Rådgivende fagkomité
Scientific Advisory Board
David E. Nichols
Adjunct Professor in the Eshelman School of Pharmacy at the University of North Carolina
David E. Nichols is a Distinguished Professor Emeritus at the Purdue University College of Pharmacy and was the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology, where he carried out teaching and research for 38 years prior to his retirement in 2012. He began studying psychedelics in 1969 while a graduate student and continued that research throughout his entire professional career, being one of only a few investigators able to research psychedelics after they were scheduled. In 1993 he founded the Heffter Research Institute (HRI), which funded the first rigorous clinical studies of psychedelics in humans after a nearly 40-year moratorium and served as its president for more than 25 years. HRI funded the groundbreaking Phase I and II studies of psilocybin for the treatment of depression, as well as substance use disorders. Dr. Nichols also synthesized the DMT used by Dr. Rick Strassman in his human studies, the MDMA that MAPS used for their Phase I and II clinical trials for PTSD, and the psilocybin used by several investigators for human clinical studies including the Phase I and II trials conducted at Johns Hopkins University by Roland Griffiths and his colleagues. He is considered the world's leading expert on the chemistry of psychedelics.
Ben Sessa
Psychiatrist and Chief Medical Officer at AWAKN Life Sciences
Ben Sessa is a consultant child and adolescent psychiatrist who has worked with young people and adults in the field of addictions and trauma-related psychiatry for over 20 years. For the last 15 years Ben has been working in the field of psychedelic research in the UK through his affiliations with Bristol University and Imperial College London, under the auspices of Professor David Nutt. He has taken part as a study doctor and as a healthy subject both receiving and / or administering MDMA, psilocybin, LSD, DMT and ketamine in multiple UK research studies. He runs a weekly UK-based medical cannabis prescribing clinic. Ben is the Chief Medical Officer at AWAKN Life Sciences, a new start-up opening Europe's first psychedelic medical clinic, in Bristol, which will be providing psychedelic therapies, therapist training courses and conducting independent psychedelic research. Ben is the co-founder and former president of Europe's largest psychedelic conference, Breaking Convention.
David Erritzoe
David Erritzoe is Clinical Senior Lecturer and Consultant Psychiatrist at Imperial College London and in CNWL NHS Foundation Trust. David conducts psychopharmacological research, using brain-imaging techniques such as PET and MRI. He was trained in PET imaging at Columbia University in New York and later undertook a PhD at University Hospital Rigshospitalet in Copenhagen. Since 2009 he has been involved in post-doc imaging research in the neurobiology of addictions and major depression at Imperial. As clinical director in the Centre for Psychedelic Research, he investigates mechanisms and therapeutic potential of MDMA, ketamine and classic psychedelics together with Prof Nutt and Dr Carhart-Harris, and in early 2021 David set up a new NHS-based psychopharmacology & psychedelic research clinic at St Charles Hospital in London.
Finn Skårderud
Norwegian author, psychiatrist, psychotherapist and professor.
Finn Skårderud, MD, PhD is a Norwegian author, psychiatrist, psychotherapist and
professor. He is adjunct professor at Norwegian School of Sports, Oslo, University of Agder, Kristiansand and South Denmark University, Odense. He is a co-founder and in the leadership of the Norwegian Institute for Mentalizing. He runs a private practice, and is sport psychiatrist collaborating with Norwegian Sport Confederation, with emphasis on preventing and treating eating disorders in sport. In 2014 Finn Skårderud founded Institute for Eating Disorders. This non-profit foundation strives to be an innovative centre of excellence for treatment, research, education and training. He has produced numerous articles, essays, books and book chapters within the fields art, literature, film, psychiatry, psychology and culture, both fiction and non-fiction.
Bjørn Grinde
Senior scientist at the Division of Mental and Physical Health at the Norwegian Institute of Public Health (FHI).
Bjørn Grinde received his education in natural sciences, psychology, and anthropology from the University of Oslo, ending with a Dr. Scient. (1981) and a Dr. Philos. (1984) in cellular and molecular biology. He is presently a senior scientist at the Division of Mental and Physical Health, Norwegian Institute of Public Health. Previously, he has served as a scientist and professor at leading universities in Norway, USA, and Japan. An important part of his research has been to understand the process of evolution, particularly how it has formed the human brain and our capacity to enjoy life. In addition to some 160 scientific papers, he authored several science books: Darwinian Happiness (The Darwin Press 2002, 2nd Edition 2012), God: A Scientific Update (The Darwin Press 2011), The Biology of Happiness (Springer 2012), Improving the Human Zoo (The Darwin Press, 2015), and The Evolution of Consciousness (Springer 2016). A recent focus has been on understanding the effect of psychedelics, and what they can teach us about the process of generating a conscious experience.
Ole Martin Moen
Philosopher and professor at OsloMet
Ole Martin Moen is a Norwegian philosopher who works primarily with applied ethics and value theory. He is Professor of Ethics at Oslo Metropolitan University and Researcher in Philosophy and Principal Investigator for the 5-year research project "What should not be bought and sold?" at the University of Oslo, funded by the Research Council of Norway. Moen's research also involves topics regarding drugs and he has published several articles in leading international journals such as Journal of Medical Ethics, Bioethics, Neuroethics and Philosophical Studies.

Attila Szabo
Attila Szabo er forsker ved Oslo Universitetssykehus og har Ph.D. i både biomedisin og moderne filosofi. Hans nåværende forskningsprosjekt fokuserer på serotonergiske psykedelika og cannabinoider, deres modulerende rolle på immunresponser og cellefunksjoner. Attila er også Editor-in-Chief ved Journal of Psychedelic Studies.

Malin Vedøy Uthaug
Malin Vedøy Uthaug har master innenfor helse- og sosialpsykologi, og en doktorgrad i nevropsykologi og psykofarmakologi ved Maastricht University. Malin jobber som post-doc ved The Centre for Psychedelic Research ved Imperial College London, ledet av Dr. Robin Carhart-Harris. Her forsker hun på effektene av 5-MeO-DMT på mental helse, bevissthet og hjerne-aktivitet.

Contact us with any convenient way:

E-mail: post@psykedeliskvitenskap.no
Social networks: Facebook

© All Right Reserved. My company Inc.
e-mail us: hello@company.cc
Made on